logo-loader
RNS
Clinigen Group PLC

Clinigen Group plc - Total Voting Rights

RNS Number : 7816R
Clinigen Group plc
31 October 2019
 

31 October 2019

 Clinigen Group plc

("Clinigen" or the "Group")

Total Voting Rights and Capital

In conformity with Rule 5.6.1 of the Disclosure Guidance and Transparency Rules, the Group notifies the market that as at 31 October 2019, Clinigen's issued share capital consists of 132,848,758 ordinary shares of 0.1 pence each with voting rights.  No shares are held in Treasury.

 

The above figure of 132,848,758 may be used by shareholders as the denominator to determine if they are required to notify their interests in, or a change to their interests in, the Group under the FCA's Disclosure Guidance and Transparency Rules.

 

-Ends-

 

Contact details

 

Clinigen Group plc

Tel: +44 (0) 1283 495010

Matt Parrish, Head of Investor Relations




Numis Securities Limited - Nominated Adviser & Joint Broker

Tel: +44 (0) 20 7260 1000

James Black / Freddie Barnfield




RBC Capital Markets - Joint Broker

Tel: +44 (0) 20 7653 4000

Marcus Jackson / Elliot Thomas




Instinctif Partners

Tel: +44 (0) 20 7457 2020

Melanie Toyne-Sewell / Rozi Morris / Phillip Marriage

Email: clinigen@instinctif.com

 

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. The Group has sites in North America, Europe, Africa and Asia Pacific.

 

Clinigen now has over 1,100 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 22 of the top 25 pharmaceutical companies; interacting with over 15,000 registered users across over 100 countries, shipping approximately 6.4 million units in the year.

 

For more information on Clinigen, please visit www.clinigengroup.com

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TVRDMMFGLMDGLZG
NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read